HF 3664

as introduced - 93rd Legislature (2023 - 2024) Posted on 03/18/2024 04:18pm

A bill for an act
relating to human services; authorizing the commissioner of human services to
provide separate reimbursement for biological products provided in the inpatient
hospital setting as part of cell or gene therapy to treat rare diseases; amending
Minnesota Statutes 2022, section 256.969, by adding a subdivision.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2022, section 256.969, is amended by adding a subdivision
to read:

new text begin Subd. 32. new text end

new text begin Biological products for cell and gene therapy. new text end

new text begin (a) The commissioner may
provide separate reimbursement to hospitals for biological products provided in the inpatient
hospital setting as part of cell or gene therapy to treat rare diseases, as defined in United
States Code, title 21, section 360bb. This payment must be in addition to the diagnostic
related group reimbursement for the inpatient admission or discharge associated with a stay
during which the patient received a product subject to this paragraph.
new text end

new text begin (b) The commissioner shall establish the separate reimbursement rate for biological
products provided under paragraph (a) based on the methodology used for drugs administered
in an outpatient setting under section 256B.0625, subdivision 13e, paragraph (e).
new text end

new text begin (c) The commissioner may require managed care and county-based purchasing plans to
comply with paragraph (a) when delivering services to medical assistance enrollees, and to
provide separate reimbursement for biological products that meets or exceeds the
reimbursement level established by the commissioner under paragraph (b).
new text end

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective January 1, 2025.
new text end